Investors are hotly anticipating the US roll out of Futura Medical plc’s drug-free erectile dysfunction gel.
While they say that there has been “limited visibility” on plans since Haleon plc signed a $4m deal with...
Haleon ‘Tight Lipped’ On US Eroxon Roll Out, But Analysts Say 2024 Launch Possible
Listen to this article
Haleon says it'll take about 10 more months to bring Futura's Eroxon erectile dysfunction gel to the US. Analysts, however, say it may even arrive before the end of the year, with Haleon already investing significantly in its launch strategy.
Explore how consumer health is evolving. On the go.
More from United States
Green Pharmaceuticals’ SnoreStop Nasal Spray, previously marketed as “NasoSpray,” still is available even though agency officials on multiple occasions for a month recommended a recall after an April inspection found “gross microbial contamination” in one lot.
• By
Global beauty giant is working to adapt its approach to the prestige market to meet escalating competition, increased points of sale, and more knowledgeable consumers with new shopping habits, CFO Tracey Travis said at the Barclays Global Consumer Staples Conference.
• By
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
More from North America
• By
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
• By
Week after publishing safety alert about OPMS Black Liquid Kratom “linked to serious adverse health effects, including death,” FDA announced market research “to understand and characterize emergent risk/safety and perceived benefits reportedly linked to kratom and psychedelics.” But it withdrew the study 10 days later.
• By
Semi-annual regulatory agenda of non-binding target dates also sets December goal for an NPRM to recognize N-acetyl-L-cysteine as a lawful dietary ingredient. Like IND exemptions rule, item on NAC included for first time in FDA’s list.